Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis: No Longer "If" but a Question of "When" to Start

Hiran Selvadurai^{1

2}

Affiliations

¹ The Children's Hospital at Westmead Sydney Children's Hospital Network Sydney, Australia.
² Discipline of Paediatrics and Child Health University of Sydney Sydney, Australia.

Editorial

Hiran Selvadurai. Am J Respir Crit Care Med. 2025 Oct.

. 2025 Oct;211(10):1895-1896.

doi: 10.1164/rccm.202505-1146ED.

Hiran Selvadurai^{1

2}

¹ The Children's Hospital at Westmead Sydney Children's Hospital Network Sydney, Australia.
² Discipline of Paediatrics and Child Health University of Sydney Sydney, Australia.

No abstract available

Comment on

Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Waltz D, Ahluwalia N, Chu C, Scirica CV, Davies JC. Wainwright C, et al. Am J Respir Crit Care Med. 2025 Oct;211(10):1915-1925. doi: 10.1164/rccm.202502-0512OC. Am J Respir Crit Care Med. 2025. PMID: 40454869 Clinical Trial.

1. Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH. et al. VX19-445-107 Study Group. Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children ⩾6 years with cystic fibrosis and at least one F508del allele: a 192-week, phase 3, open-label extension study. Am J Respir Crit Care Med . 2025;211:1915–1925. - PubMed
1. Zemanick ET, Taylor-Cousar JL, Davies J, Gibson RL, Mall MA, McKone EF. et al. A phase 3 open label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508 allele. Am J Respir Crit Care Med . 2021;203:1522–1532. - PMC - PubMed
1. Wainright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH et al. Long term safety and efficacy of Elexacaftor/Tezacaftor/Ivacaftor in children ≥6 year with cystic fibrosis. Am J Resp Crit Care Med . 2023 - PMC - PubMed
1. Gabillard-Lefort C, Casey M, Glasgow AMA, Boland F, Kerr O, Marron E. et al. Trikafta rescues CFTR and lowers monocyte P2X7R-induced inflammasome activation in cystic fibrosis. Am J Respir Crit Care Med . 2022;205:783–794. - PubMed
1. Ratner D, Mueller C. Immune responses in cystic fibrosis: are they intrinsically defective? Am J Respir Cell Mol Biol . 2012 - PubMed